Cooperative Agreement U01AI078205

Federal Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 11, 2025, with performance completion targeted for August 31, 2026. The award funds the development of a microneedle-based messenger RNA (mRNA) flu vaccine designed for transcutaneous (intradermal) immunization. Leveraging the company's proprietary...

Federal Grant Award Summary L2 Diagnostics LLC received a $281,786 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 23, 2025, with a completion date of August 31, 2027. The grant funds the development of a Modified Vaccinia Ankara (MVA) vector-based vaccine designed to protect against Powassan virus (POWV) infection. The vaccine incorporates surface proteins (E and PRM)...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Washington University a Project Grant of $155,454 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025, through July 31, 2027. This award funds research to identify and characterize molecular mechanisms of Venezuelan Equine Encephalitis Virus (VEEV) entry into host cells and to develop enhanced therapeutic interventions targeting...

Summary of Federal Project Grant Award Viva Viral Vaccines, Inc. received a $299,968 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a broad-spectrum, multivalent vaccine platform targeting pan-influenza protection. The award, issued on September 25, 2025, with a completion date of August 31, 2026, supports the company's work in Ithaca, NY to advance a novel influenza...

Mapp Biopharmaceutical, Inc. received a $993,353 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 24, 2025, with performance extending through August 31, 2028. The grant supports the development of MBP002, a fully human monoclonal antibody (MAb) cocktail product designed for respiratory syncytial virus (RSV) immunoprophylaxis. MBP002 is engineered as a single-dose,...

Grant Award Summary Children's Mercy Hospital received a $433,175 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. The award supports the development of a mosaic messenger ribonucleic acid (mRNA) vaccine designed to prevent hand, foot, and mouth disease (HFMD) caused by human enterovirus A viruses. The research deliverables include the design...

This Project Grant award from the National Institute of Allergy and Infectious Diseases supports the development of a novel plant-based source for squalene as a natural vaccine adjuvant. The $514,006 award to Synshark LLC supports research to engineer tobacco plants to stably produce and accumulate squalene on their leaves. This work directly relates to the commercialization plan to provide a non-animal, indoor grown natural adjuvant for vaccines. Currently, squalene used in vaccines is...

Federal Grant Award Summary Vaxiion Therapeutics, LLC received a $306,265 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 16, 2025, with a completion date of August 31, 2026. The award supports the preclinical development of VAX024, a novel targeted combination oncolytic agent incorporating a Stimulator of Interferon Genes (STING) agonist. VAX024 utilizes Vaxiion's proprietary recombinant bacterial minicell delivery...

This three-year, $1 million Project Grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) supports the development of viral vectors for gene delivery and manipulation in amphibian research. The Trustees of Columbia University will lead efforts to design new viral vectors with host specificity for amphibians. Researchers at Columbia, the Institute of Science and Technology Austria, the University of Utah, and the Scripps Research Institute will collaborate to test...